STOCK TITAN
  1. Home
  2. News
  3. OGEN

Oragenics Inc - OGEN STOCK NEWS

Welcome to our dedicated news page for Oragenics (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oragenics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oragenics's position in the market.

News
Oragenics Announces Termination of At-The-Market Offering Program
Rhea-AI Summary
Oragenics, Inc. (NYSE American: OGEN) has terminated its 'at-the-market' equity offering program, with the termination to take effect on January 30, 2024. The Company will make no sales under the ATM offering during this period. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
none
-
News
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
Rhea-AI Summary
Oragenics, Inc. (NYSE American: OGEN) has completed the acquisition of assets related to Odyssey Health, Inc.'s proprietary neurological drug therapies and technologies, including ONP-002 and a unique nasal delivery device. The acquisition aims to develop innovative treatments for moderate-to-severe concussion and Niemann Pick Type-C Disease (NPC), addressing a significant market opportunity. Michael Redmond has been named President of Oragenics, bringing 35 years of commercial experience with medical device companies to oversee the growth of Oragenics' neurology product pipeline and intranasal drug delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.43%
Tags
acquisition
-
News
Oragenics Issues Update to Shareholders
Rhea-AI Summary
Oragenics, Inc. announces the acquisition of Odyssey Health, Inc.'s lead assets, including proprietary neurological drug therapies. The assets have potential for enhancing shareholder value and expanding the market reach. The global market for concussion treatment is valued at $6.9 billion in 2020 and projected to reach $8.9 billion by 2027. The market for Niemann Pick Disease Type C is projected to increase from $128 million in 2022 to $188 million in 2031. The acquisition also brings a team of talented scientists to enhance research and development efforts. Proposal 3 of the 2022 Annual Meeting involves increasing the authorized common stock to support the acquisition and raise capital for ongoing research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
News
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
Rhea-AI Summary
Oragenics, Inc. announces the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
management
-
News
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
Rhea-AI Summary
Oragenics to acquire Odyssey Health's assets related to neurological drug therapies and technologies, including drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as a proprietary powder formulation and nasal delivery device. The transaction includes $1.0 million in cash payments and eight million shares of Oragenics' Series F Convertible Preferred Stock. The deal is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.71%
Tags
acquisition
-
News
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
Rhea-AI Summary
Oragenics and Lantern Bioworks announce a partnership to potentially revolutionize dental caries prevention. Oragenics receives $50,000 and an opportunity to acquire one million shares of Lantern Bioworks' equity. Lantern Bioworks will pay Oragenics a 10% royalty on net income from transferred assets. Dental caries remains a global health challenge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Oragenics, Inc. Announces Private Placement
Rhea-AI Summary
Oragenics announces private placement offering with healthcare-focused investors, raising approximately $840,000 in gross proceeds. The Company intends to use the net proceeds for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
News
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
covid-19
-
News
Oragenics to Participate in the World Vaccine Congress Washington
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
News
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
Stock OGEN logo
Oragenics Inc

NYSE:OGEN

OGEN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OGEN Stock Data

5.51M
3.95M
23.32%
7.37%
0.92%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Tampa

About OGEN

oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies. offerings are based on the probiora3 technology and brands include evoraplus™ is a new, one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth. oragenics has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.